Magenta Elevate™ study for cardiogenic shock
Part of Heart & circulation clinical trials.
This trial tests a new heart pump called the Magenta Elevate™ to help people whose heart suddenly stops pumping enough blood (cardiogenic shock). It aims to improve blood flow and reduce strain on the heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been in cardiogenic shock for less than 24 hours.
- Your heart's pumping ability is between 15% and 45%.
- The right side of your heart is working well or only mildly affected.
- You are not having other causes of shock like severe infection or blood clot in the lungs.
- You do not have a recent stroke or serious bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a device that helps the heart pump blood when it is too weak to do so, even with medicine, after surgery, or while waiting for a transplant. It aims to see if it's safe and works well.
This trial tests a new heart pump (Impella device) for people who have a severe heart attack and go into shock (very low blood pressure). It aims to see if the pump can help the heart recover better than standard care.
This trial tests whether using a temporary heart pump plus close monitoring improves recovery in people with severe heart failure after a heart attack, compared to standard care.
This trial tests if unloading the heart during ECMO support helps patients recover better from cardiogenic shock. It compares different ways to reduce the heart's workload.
This trial is testing a temporary heart pump device that helps your heart pump blood when it's too weak to do its job. It's for people who have severe heart failure (cardiogenic shock) despite getting powerful medications to keep their heart working.
This trial studies whether putting in a small heart pump early (through the leg) helps people with a heart attack complicated by severe heart weakness (“cardiogenic shock”) compared with standard treatment. It aims to improve survival and recovery by supporting blood flow sooner.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.